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Abstract 
 
Background: Vancomycin is a cornerstone antibiotic for the management of severe Gram positive 
infections. However, high doses of vancomycin are associated with a risk of nephrotoxicity. This study 
aimed to evaluate the relationship between the evolution of vancomycin trough concentration and the 
occurrence of nephrotoxicity, and to identify risk factors for both vancomycin-associated nephrotoxicity 
and vancomycin overexposure. 
Methods: A total of 1240 patients records from our hospital therapeutic drug monitoring database 
between 2007 and 2011 were screened and grouped according to predefined criteria defining 
vancomycin overexposure (one or more occurrence of a trough  level ≥ 20 mg/L) and treatment-related 
nephrotoxicity (rise of serum creatinine by ≥ 50% over baseline). A representative sample of 150 cases 
was selected for in depth analysis. Weighted logistic regression analyses were used to test associations 
between vancomycin overexposure, nephrotoxicity and other predictors of interest.  
Results: Patients with high trough concentrations were found to be more likely to develop 
nephrotoxicity (odds ratio: 4.12; p <0.001). Specific risk factors, notably concomitant nephrotoxic 
treatments and comorbid conditions (heart failure), were found to independently increase the risk of 
either nephrotoxicity or vancomycin exposure. Finally, the exploration of temporal relationships 
between variations of vancomycin trough concentrations and creatinine levels were in line with circular 
causality with some antecedence of vancomycin on creatinine changes. 
Conclusion: Our results confirm the important nephrotoxic potential of vancomycin and indicate that 
the utilisation of this drug deserves thorough individualization for conditions susceptible to increase its 
concentration exposure and reactive adjustment based on therapeutic drug monitoring.  
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Background 
 
1. Vancomycin: a half century of fighting infection. 
 
Vancomycin is a tricyclic glycopeptide antibiotic discovered in 1953. It is a large and complex molecule 
with a molecular weight of approximately 1500 Daltons, naturally produced by an Actinobacterium 
species called Streptomyces orientalis. It has been licensed for clinical use since 1958. However, adverse 
effects due to impurities in early formulations of vancomycin, humorously called "Mississippi mud", 
restrained its expansion in the clinical world (1,2). Renewed interest for vancomycin appeared with the 
emergence of resistance to beta-lactam antibiotics. Beta-lactam resistant bacteria, such as Methicillin-
resistant Staphylococcus aureus (MRSA), are important causative agents of both community-acquired 
and nosocomial infections today. Treatment options for these infections are limited and less effective 
than options available for non-resistant bacteria, resulting in higher morbidity and mortality (3,4,5). 
Vancomycin is nowadays a keystone for the control of severe Gram-positive infections, including those 
due to beta-lactam resistant pathogens (2,6,7,8). 
This effectiveness is explained by a different mechanism of action compared to classic beta-lactam 
antibiotics, although both types of drugs inhibit cell wall synthesis. Beta-lactam antibiotics bind to 
transpeptidase enzymes, which catalyse the growth of the peptidoglycan layer, a major component of 
cell walls. Vancomycin binds directly to a cell wall precursor, preventing its incorporation into the 
peptidoglycan layer (8,9). The bactericidal effect resulting from this inhibition of cell wall synthesis is 
quite slow to develop. Vancomycin is so known as a "time-dependent killer", meaning that it is effective 
only if the antibiotic's concentration at the target site remains higher than the minimum inhibitory 
concentration (MIC) of targeted pathogen for the longest possible time (9,10). Vancomycin effectiveness 
has also been correlated with the ratio of the area under serum vancomycin concentration curve (AUC) 
over the MIC. An AUC/MIC ratio >400 is associated with better outcome in complicated infections (7,11). 
Considering pharmacokinetic parameters, vancomycin is poorly absorbed from the gastrointestinal 
tract. The main route of administration is therefore the intravenous route, except for the treatment of 
Clostridium difficile colitis where oral therapy is indicated to produce local bacterial killing in the gut 
lumen. The binding of vancomycin to plasma proteins is around 55% and its volume of distribution 
ranges from 0.4 to 1 L/kg. Mean elimination half-life from plasma is approximately 4 to 6 hours in 
patients with normal renal function. Vancomycin is not metabolized in the body and mainly eliminated 
by the kidneys via glomerular filtration. Biliary excretion is a minor (5-10%) excretion pathway of 
vancomycin (8,9,12). 
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Vancomycin has a wide spectrum of action on Gram-positive bacteria, being effective on most of 
Staphylococcus, Streptococcus, Enterococcus and Clostridium species. Due its molecular size, it cannot 
cross the outer layer of Gram-negative bacteria, thus lacking efficacy against them (1,8). Vancomycin is 
usually administrated by intermittent intravenous infusions every 6 to 12 hours. Continuous infusion is 
another administration option. Despite faster attainment of therapeutic concentrations using 
continuous infusion, no significant advantages were shown regarding clinical outcomes. (1,13) 
Administration should be slow (infusion rate <1g/h) to avoid pseudo-hypersensitivity reactions such as 
the "red man syndrome”.  
As it happened with other antibiotics, resistance is also emerging against vancomycin. Some 
occurrences of Staphylococcus aureus strains, including MRSA, revealing resistance to vancomycin have 
been reported several times in the United States since the beginning of the 21st century. Resistance has 
also been described involving Enterococcus species or other Staphylococcus species, such as the VRSE 
(Vancomycin resistant Staphylococcus epidermidis). This resistance phenomenon is quite a matter of 
concern, as recent guidelines for the treatment of severe Gram-positive infections, especially those due 
to MRSA, enacted by the Infectious Diseases Society of America (IDSA) widely recommend vancomycin 
use (8,9,14,15). 
In a 2009 major consensus review (9), the American Society of Health-System Pharmacists, the 
Infectious Diseases society of America and the Society of Infectious diseases Pharmacists have 
established guidelines for vancomycin therapy and therapeutic drug monitoring (TDM). Trough 
concentrations (i.e. residual levels of vancomycin in plasma at the end of a dosage interval) should 
always be maintained >10 mg/L to avoid the development of resistance (16). The traditional dosage for 
an adult without renal dysfunction is 1 g every 12 hours (15 mg/kg b.i.d.) (9). The target trough 
concentration proposed in complicated infections, such as MRSA infections, is 15 – 20 mg/L. Higher 
doses than the classical 1 g b.i.d. often need to be given to reach this level of exposure. According to the 
consensus guideline, TDM of vancomycin should be performed using trough concentrations rather than 
peak concentrations and the monitoring samples should be drawn just before the fourth dose 
administration under steady regimen, at least for patients with normal renal function. Monitoring 
should be performed on a weekly basis, although severe clinical conditions and known, or suspected, 
renal dysfunction indicate for more frequent monitoring. (9,17-20) 
As previously said, vancomycin is known since its first use in clinics for adverse effects. As it is very 
irritating for tissues, local complications such as or thrombophlebitis or even necrosis (in case of 
extravascular administration) can occur. Hypersensitivity-like reactions are also described, such as the 
"red-man syndrome" in which patient develops flush or maculopapular rash localized most frequently 
on face, neck, chest and upper limb, due to histamine release from granulocytes. In rare cases, a severe 
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reaction can occur with blood pressure collapse, dyspnea or angioedema, becoming life-threatening for 
patient. Rare adverse effects involving gastrointestinal tract (pseudomembranous colitis) and 
haematological disorders (leucopoenia, thrombocytopenia) are also described (8). But the most 
frequent concerns regarding vancomycin therapy remain ototoxicity and nephrotoxicity. Cochlear 
ototoxicity is indeed reported to occur with 2-5% of patients. It results from dose and duration-
dependent toxicity, thus its occurrence is usually associated with high plasmatic concentrations of 
vancomycin (greater than 60 mg/L) over prolonged times (8,9). 
 
2. Nephrotoxicity: the other side of the coin. 
 
Vancomycin-associated nephrotoxicity remains an important matter of concern since vancomycin has 
been approved for clinical use. As said before, impurity in early formulations was associated with a high 
occurrence of nephrotoxicity. Nowadays, impurities are not a problem anymore, but nephrotoxicity is 
still known as a frequent adverse effect of vancomycin therapy. As of today, this is well documented and 
described through many studies and reports (1-2,6-9,11,21).  
In both studies and clinical practice, nephrotoxicity is usually defined as a rise of 50% or more for at 
least two consecutives serum creatinine measurements over baseline, that occurs during vancomycin 
therapy or during 72h after vancomycin interruption (1,6,7,22). Nephrotoxicity is described as 
reversible in most of the cases following treatment interruption or adjustment. (7-9). Permanent renal 
damage is infrequently reported. Acute tubular necrosis is the main toxic action observed in kidney. The 
mechanism leading to nephrotoxicity remains unclear but seems to be related with oxidative stress on 
renal proximal tubule cells after intracellular penetration of vancomycin. Some studies have indeed 
shown increased oxygen consumption in those cells after vancomycin administration. Cases of 
interstitial nephritis involving an immuno-allergic mechanism have also been reported (2,7,21,23,25). 
Emergence of resistant pathogens, such as Methicillin-Resistant Staphylococcus Aureus (MRSA), has led 
to target higher vancomycin concentrations for ensuring therapeutic effect. However, it is also known 
that the administration of doses required to achieve the higher exposure targeted in this condition 
increases significantly the risk of nephrotoxicity (2,6,7,11,22). Incidence of vancomycin-associated 
nephrotoxicity is quite variable between studies but it is most commonly reported to occur in 10-20% 
of patients with a targeted trough-concentration 10-15 mg/L, but in 30-40% of patients with high doses 
therapy (targeted trough 15-20 mg/L) (1,2,5,16,21). Available observations suggest an increased risk 
of nephrotoxicity for vancomycin trough-concentrations over 20 mg/L or daily doses >4g (7,24). 
Concomitant exposure to other known nephrotoxic agents or to treatments causing pre-renal 
dysfunction, such as aminoglycosides antibiotics or diuretics, is also described as a risk factor for 
induced nephrotoxicity. (1,2,5,6,11,14,26)  
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As vancomycin is both eliminated by and toxic to the kidneys, there is thus a bidirectional relationship 
between nephrotoxicity and vancomycin overexposure. Indeed, during the recent past, hospital 
consultants from the Division of Clinical Pharmacology have been referred a certain number of patients 
for the development of renal failure occurring under vancomycin treatment and associated with high 
trough concentrations. Clinically, the causation link between overexposure and nephrotoxicity is quite 
difficult to assess, as they both are the consequence from one another but could both contribute to the 
occurrence of the other. This could be described as a vicious circle, bringing out a “chicken-and-egg” 
problem: what occurs first?  
 
 
 
 
In this context, devising preventive measures to improve the therapeutic use of vancomycin and to 
control its toxic potential represents a challenging task. A better understanding of how this circular 
causality works and of how it is further influenced by various risk factors could possibly contribute to 
improve the recommendations for an effective and safe use of this important antibiotic.  
 
3. Study aims 
 
This retrospective case-control study aims to evaluate the relationship between vancomycin trough 
concentrations and the development of nephrotoxicity, to identify risk factors associated with 
vancomycin-associated nephrotoxicity, to identify risk factors for vancomycin overexposure itself and 
to explore the temporal link between the rise of vancomycin trough concentrations and the rise of serum 
Renal toxicity
Impairment of 
renal function
Vancomycin 
clearance ↓
Vancomycin 
accumulation
Vancomycin 
trough 
concentration ↑
Creatinine 
follow-up 
TDM  
Fig.1: Vicious circle and ways to interfere with it.  
Other factors of 
susceptibility  
Dosage 
decisions  
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creatinine levels. Recommendations regarding monitoring and adjustments during vancomycin therapy 
could eventually be brought out from these observations.  
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Methods 
 
1. Study design and data collection 
 
This retrospective case-control study was conducted in the University Hospital of Lausanne (CHUV) in 
Switzerland. The Ethics Committee of the Faculty of Biology and Medicine in Lausanne has approved the 
study. Patients were recruited from the hospital laboratory database (MOLIS, Vision4Health, 
CompuGroup Medical, Oechsli 7, 8807 Freienbach, Switzerland). We first identified all patients who 
received vancomycin therapy between January 2007 and December 2011, and who had at least one 
vancomycin concentration measurement (recruitment criterion). We included in the study adults 
patients (≥16 years old), hospitalized in non-intensive care units, and for whom serum creatinine 
measurements were available in a timespan of one month surrounding first and last recorded 
vancomycin trough-concentration (selection criteria). A stay in the intensive care unit for less than 72 
hours during vancomycin therapy was admitted and did not exclude the patient from the study. Patients 
who underwent dialysis or for whom blood sampling or vancomycin measurements times were unclear 
or unknown were excluded. 
 
For patients meeting the selection criteria, we extracted the following data from the laboratory 
database: 
 Date and time of blood sampling for all recorded vancomycin trough-concentrations 
measurements, with date and time of the last vancomycin administration and vancomycin dosage 
at the time of blood sampling. 
 Date and time of blood sampling for all recorded serum creatinine measurements. 
 If recorded, date and time of blood sampling for vancomycin peak-concentrations measurements, 
with date and time of the last vancomycin administration and vancomycin dosage at the time of 
blood sampling. 
 
In order to later discriminate between cases and controls, patients were grouped on the basis of two 
criteria: occurrence of vancomycin overexposure (V criterion) and occurrence of vancomycin-
associated nephrotoxicity (C criterion). Overexposure was defined in our study as the existence of at 
least one vancomycin trough concentration ≥20 mg/L (V1; V0 otherwise). Vancomycin-associated 
nephrotoxicity was defined as a rise by ≥50% of serum creatinine levels from baseline for two 
consecutive measures, occurring during vancomycin therapy or within 72 hours after therapy 
interruption (C1; C0 otherwise).  
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The identification of patients actually matching C1 criterion required a two-steps process, as data from 
MOLIS (laboratory database) did not allow the determination of the period of vancomycin therapy and 
creatinine baseline. In the first step, we screened the patient with a rise ≥ 50% of creatinine levels 
between any of two measures in a one-month timespan surrounding first and last recorded vancomycin 
trough-concentration (C1’; C0 otherwise). 4 groups of patients were then defined within the “screened 
population”: 
 Group V0C0: vancomycin trough-concentrations <20 mg/L and rise of creatinine by <50% between 
two measures. 
 Group V0C1’: vancomycin trough-concentrations <20 mg/L and rise of creatinine by ≥50% 
between two measures. 
 Group V1C0: at least one vancomycin trough-concentration ≥20 mg/L and rise of creatinine by 
<50% between two measures. 
 Group V1C1’: at least one vancomycin trough-concentration ≥20 mg/L and rise of creatinine by 
≥50% between two measures. 
 
The second step consisted in a random selection of patients matching C1’ (i.e patients belonging either 
to V0C1’ or V1C1’ group) for intensive data extraction from the hospital medical records (ARCHIMED 
database). This closer analysis of patients records was done in order to determine the date of onset and 
duration of vancomycin therapy, creatinine baseline value and occurrence of vancomycin-associated 
nephrotoxicity as defined earlier (C1). Creatinine baseline value was calculated as the average of the 
last 3 values of creatinine prior the antibiotic therapy start. Patients who matched the preliminary rough 
C1’ criterion but failed to match the final C1 criterion were excluded. As this two steps process 
(screening and detailing) was time consuming, we proceeded to review only a fraction of patients in 
both the V0C1’ and V1C1’ groups. In each group, the total number of patients matching the C1 criterion 
was extrapolated from the number of records that had to be reviewed to obtain 25 patients matching 
the C1 criterion. At the end, the “reviewed population” contained 4 groups as follows: 
 Group V0C0: neither vancomycin overexposure nor vancomycin-associated nephrotoxicity. 
 Group V0C1: no vancomycin overexposure but vancomycin-associated nephrotoxicity. 
 Group V1C0: vancomycin overexposure without associated nephrotoxicity. 
 Group V1C1: both vancomycin overexposure and associated nephrotoxicity. 
 
Alongside the 25 patients in V0C1 and V1C1 groups, 50 patients in both V0C0 and V1C0 were randomly 
selected. We recorded demographic characteristics, comorbid conditions, pathogens involved, sites of 
infection, clinical circumstances leading to vancomycin therapy and exposure to other known potential 
nephrotoxic therapy. The detailed list of recorded items is shown in appendix 1. The chronological 
course of vancomycin therapy was rebuilt for every patient, with time of onset and interruption of 
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therapy, detailed vancomycin dosage, time of vancomycin trough or peak concentration measurements 
(including time since the last vancomycin administration), time of creatinine measurements and 
variations of creatinine levels from baseline. These data allowed to further calculating various 
parameters for every patient, such as average or maximal vancomycin doses per day; cumulated doses 
administrated over therapy, average and maximal trough or peak-concentrations observed or minimal 
and average and maximal creatinine levels. These data were subject in another analysis to population 
pharmacokinetic modelling, allowing to retrieve the maximum likelihood value of some 
pharmacokinetic parameters for vancomycin (27). The patients’ glomerular filtration rate was 
estimated as well using Cockcroft-gault and MDRD formulas1. All of the recorded data were then 
investigated as potential predictors of vancomycin-associated nephrotoxicity or vancomycin 
overexposure. 
 
2. Group population description 
 
A description of the four reviewed groups was first conducted. Summary tables were used to describe 
demographic characteristics and other data mentioned above. Chronological course of vancomycin 
therapy was graphically represented for every patient. 
 
3. Relationship between vancomycin overexposure and associated nephrotoxicity. 
 
The association between vancomycin overexposure and vancomycin-induced nephrotoxicity was 
assessed using a Chi-square test as the main working hypothesis of the study. It was performed on both 
screened groups population and reviewed groups’ population, although only the result on the reviewed 
population was considered. The reason is that the screened population contains a number of “uncertain” 
patients dropped out for not matching the C1 criterion. These patients were completely dropped out of 
the analysis and not included in the C0 groups, to avoid contamination by a possibly higher number of 
patients with renal problems related or not to vancomycin, yet not corresponding to our definition of 
vancomycin-associated nephrotoxicity.  
  
                                                             
1 Cockcroft-gault : creatinine clearance = ((140 - age in years) x (weight in kg) x K) / (serum creatinine in 
µmol/l), where K is 1.23 for men and 1,04 for women 
MDRD: eGFR = 186 x (creatinine in µmol/l x 0,0113)-1,154 x age- 0,203 (x 0.742 for women or 1.21 african-american) 
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4. Assessment of hypothesized risk factors for vancomycin-associated nephrotoxicity. 
 
Hypothesized risk factors for vancomycin-associated nephrotoxicity were assessed using a logistic 
regression approach. Results were contrasted between a non-nephrotoxic group (V0C0 + V1C0 
patients) and a nephrotoxicity group (V0C1 + V1C1 patients), regardless of the level of vancomycin 
exposure. As the sample size of our reviewed groups had been artificially limited to 25 or 50, the group 
samples had to be weighted for the Chi-square test in order to represent their actual abundance in the 
original population of patients receiving vancomycin. We used the “sampling weight” option in STATA, 
i.e. a weighting factor proportional to the inverse of the probability that the patient is included in the 
analysis due to sampling strategy. This type of weighting is assumed not to unduly affect the significance 
levels. . Beyond vancomycin overexposure (main working hypothesis), all other potential risk factors 
for nephrotoxicity listed in appendix 1were first evaluated using univariate analyses. Some associations 
were excluded as they were evidently constructed. Multivariate analysis was then performed for 
confirmation, first without and then with inclusion of vancomycin overexposure as risk factor. A 
stepwise approach was used to select variables to include in the multivariate model.  
 
5. Assessment of hypothesized risk factors for vancomycin overexposure. 
 
Hypothesized risk factors for vancomycin overexposure were also assessed using a weighted logistic 
regression approach. In this analysis, results were contrasted between a non-overexposed group (V0C0 
+ V0C1 patients) and an overexposed group (V1C0 + V1C1 patients). Here again, the weighting of group 
samples was required to represent their frequency in the original population. Vancomycin-associated 
nephrotoxicity as risk factor for vancomycin exposure (main working hypothesis) was evaluated, and 
univariate analyses were then used to test associations between vancomycin overexposure and other 
potential risk factors listed in appendix 1. Some associations were excluded due to constructed 
correlation. A stepwise multivariate confirmatory analysis was then performed, first without and then 
with inclusion of induced nephrotoxicity as risk factor.  
 
6. Temporal link between vancomycin and creatinine changes. 
 
An exploration of the temporal link between vancomycin trough-concentrations and creatinine 
variations was attempted, keeping only the values of vancomycin trough-concentrations measured on 
the same day as a creatinine value. Spearman’s rank correlation was computed to assess the association 
between same day vancomycin and creatinine values. Cross correlations with Spearman’s method were 
then used to assess the associations between given vancomycin values and anterior or posterior 
creatinine levels (up to 3 lag shifts each). Similarly, cross-associations were determined between 
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vancomycin dosages and trough-concentrations, both simultaneous and lagged in the past or in the 
future (up to 3 lag shifts each). We also assessed similarly the cross-associations between vancomycin 
dosage and creatinine levels. This determination of precedence in trends has been advocated to evaluate 
the direction of potential causality relationships between multiple longitudinal variables. Finally, we 
applied to the series of vancomycin and creatinine values a formal Granger causality test, aiming to 
determine whether one time series is able to forecast another one better than the mere previous values 
of the second one.  
 
All statistical analyses were performed using the STATA software (version 13.1, StataCorp, 4905 
Lakeway Drive, College Station, Texas 77845 USA). Test significance throughout our analyses was 
considered for p values smaller than 0.05 (P<0.05). 
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Results 
 
1. Descriptive analysis 
 1.1 Study population 
 
 Extrapolated number of patients in reviewed population example: 25 out of 85 patients (=29.4%) from 
V0C1’ group (n=364) matching C1 criteria when reviewed. Total number of patients matching V0C1 in 
reviewed population is so defined as 29.4% of V0C1’ screened population, i.e 29.4% from 364 = 107 
patients. 
 
Figure 2: Flow chart depicting the selection process of patients included in the study. 
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1240 patients were included from the hospital laboratory database, composing the screened population. 
150 patients were randomly selected from the screened population groups and included in the full 
analysis after extensive review of their medical records: 50 from V0C0, 25 from V0C1, 50 from V1C0 
and 25 from V1C1. During the reviewing process, 404 patients matching the C1’ criterion were dropped 
out of the analysis as they didn’t truly match the definition of vancomycin-associated nephrotoxicity as 
earlier defined (i.e. C1 criterion). The patients reviewed and kept in the analysis were used to calculate 
and extrapolate the frequency of true V0C1 and V1C1 cases in the whole study population. At the end, 
836 patients were considered as truly matching V and C criteria, composing the reviewed population. 
Thus, each of the 50 patients extensively reviewed among the 540 assigned in group V0C0 was given a 
weight of 540/50=10.8 during further analyses; each of the 25 reviewed among the 107 in group V0C1 
was weighted 4.28; each of the 50 reviewed among 104 in group V1C0 was weighted 2.08; and each of 
the 25 reviewed among 85 in group V1C1 was weighted 3.40. These “sampling weights” represent the 
inverse of the probability that each patient was included in the analysis considering the sampling 
strategy, and are used to compute association coefficients corrected for sampling inequity, without 
unduly affecting the significance levels. 
 
Demographic characteristics and clinical data extracted from hospital medical records are summarize 
for every sample groups in appendix 2. The mean age (± SD) was quite similar between groups, ranging 
from 63.3 (±16.4) to 69.8 (±13.7) years. In V0C0, V0C1 and V1C0 groups, the sex ratio male/female was 
close to 60/40%, but was 80/20% in V1C1. The most frequent comorbid conditions were arterial 
hypertension and diabetes. Arterial hypertension occurred approximately 1.5 times more often in V1C0 
than in the other groups (60 vs 38-44%). Pre-existent heart failure was more than two times more 
prevalent in V1C1 (52 vs 18-20%). Skin and soft tissues infections were predominant in V0C0 and V1C0 
groups (42 and 38% vs 20 and 24% in the other groups). V1C1 patients suffered twice more than others 
from bloodstream infection (44 vs 16-18%).  
 
MRSA and Staphylococcus epidermidis were the most frequent pathogens found in every group, with 22, 
32, 38 and 56% in V0C0, V0C1, V1C0 and V1C1 groups respectively for MRSA and 30, 24, 20 and 28% 
respectively for S. epidermidis. Vancomycin therapy was mostly started in a febrile state context or close 
from a surgical act complicated with an infection requiring vancomycin. 96% of patients in whom 
nephrotoxicity occurred (V0C1 and V1C1) received at least one other potentially nephrotoxic treatment 
(and/or causing pre-renal dysfunction) during vancomycin therapy, when only 64 and 74% received 
one in V0C0 and V1C0 respectively. Diuretics and NSAIDs were the most frequent treatments 
administrated. It is interesting to note a marked difference between groups regarding aminoglycosides 
and anti-fungal agents, far more prevalent in V0C1 and V1C1.  
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Patients received vancomycin for an average of 14.2 (±10.5) days in V0C0, 14.9 (±10.5) days in V0C1, 
15.2 (±10.6) days in V1C0 but 24 (±16) days in V1C1. The mean daily dose was quite similar, ranging 
from 1.2 – 1.6°g. The average cumulated dose received was again quite similar for V0C0, V0C1 and V1C0 
groups with 22.4 (±19.5)°g, 22.0 (±17.5)°g, 23.1 (±18.05)°g respectively but higher in V1C1 with 30.9 
(±25.3)°g. 
 
1.2. Relationship between vancomycin-associated nephrotoxicity and overexposure. 
 
In the reviewed population, the global incidence of vancomycin-associated nephrotoxicity was 
estimated to be 23% (192 out of 836 patients). More specifically, according to our definition, 
nephrotoxicity occurred in 16.5% of patients without vancomycin overexposure (107 out of 647 
patients) versus 45% of patients with vancomycin overexposure observed (85 out of 189). A Chi-square 
test confirmed vancomycin-induced nephrotoxicity to be significantly associated with vancomycin 
overexposure, with an odds ratio of 4.12 ([95%CI] = 2.85 – 5.96, p <0.001). This result is in line with our 
main working hypothesis. 
 
2. Assessment of hypothesized risk factors.  
 
The variables retrieved from patient records were assessed as hypothesized risk factors for 
vancomycin-induced nephrotoxicity. They were contrasted between a non-nephrotoxic group (V0C0 + 
V1C0, n=100) and a nephrotoxic group (V0C1 + V1C1, n=50) as defined earlier. The same process was 
applied thereafter to assess risk factors for vancomycin overexposure. Variables contrasted according 
to both these classifications are summarized in the table below, with the most frequent comorbid 
conditions, pathogens involved, sites of infection, clinical conditions and nephrotoxic co-treatment put 
in bold. 
 
Variables Non-nephrotoxic 
group (n=100) 
Nephrotoxic 
group (n=50) 
Non-overexposed 
group (n=75) 
Overexposed 
group (n=75) 
Population characteristics     
Age, mean years (±SD) 66.6 (±15.4) 67.8 (±13.9) 64.2 (±15.4) 69.8 (±13.9) 
Sex %male (% female) 60 (40) 70 (30) 61.3 (38.7) 65.3 (34.7) 
Body weight, mean kg (±SD) 74.9 (±17.2) 81.02 (±17.07) 78.8 (±17.2) 75.11 (±17.3) 
Obesity (%) 22 (22) 16 (32) 21.0 (28.0) 17.0 (22.7) 
Comorbid conditions     
Arterial hypertension (%) 49 (49) 21 (42) 30 (40) 40 (53.3) 
Pre-existent renal failure (%) 19 (19) 18 (36) 14 (18.7) 23 (30.7) 
Heart failure (%) 21 (21)  14 (28) 9 (12)  26 (34.7) 
Diabetes mellitus (%) 31 (31) 13 (26) 22 (29.3) 22 (29.3) 
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Pathogens      
MSSA (%) 4 (4) 2 (4) 4 (5.3) 2 (2.7) 
MRSA (%) 30 (30) 22 (44) 19 (25.3) 33 (44) 
S. Epidermidis (%) 25 (25) 13 (26) 21 (28) 17 (22.7) 
Streptococcus species (%) 6 (6) 1 (2) 5 (6.7) 2 (2.7) 
Enterococcus species (%) 19 (19) 7 (14) 11 (14.7) 15 (20) 
Unidentified pathogen (%) 14 (14) 7 (14) 14 (18.7) 7 (9.3) 
Other (%) 6 (6) 6 (12) 6 (8) 6 (8) 
Site of infection     
Bloodstream (%) 18 (18) 15 (30) 13 (17.3) 20 (26.7) 
Bone (%) 10 (10) 4 (8) 6 (8) 8 (10.7) 
Prosthetics (%) 13 (13) 5 (10) 8 (10.7) 10 (13.3) 
Skin and soft tissues (%) 40 (40) 11 (22) 27 (36) 24 (32) 
Endocarditis (%) 2 (2) 3 (6) 4 (5.3) 1 (1.3) 
Pneumonia (%) 2 (2) 3 (6) 3 (4) 2 (2.7) 
Meningitis (%) 4 (4) 0 (0) 3 (4) 1 (1.3) 
Intra-abdominal (%) 1 (1) 2 (4) 2 (2.7) 3 (4) 
Other (%) 14 (14) 7 (14) 9 (12) 6 (8) 
Clinical conditions     
Surgery (%) 40 (40) 16 (32) 26 (34.7) 30 (40) 
Febrile neutropenia (%) 5 (5) 3(6) 6 (8) 2 (2.7) 
Fever (%) 30 (30) 17 (34) 25 (33.3) 22 (29.3) 
Septic shock (%) 3 (3) 4 (8) 3 (4) 4 (5.3) 
Malignancy (%) 1 (1) 1 (2) 1 (1.3) 1 (1.3) 
Other (%) 21 (21) 9 (18) 14 (18.7)  16 (21.3) 
Concomitant exposure to      
Nephrotoxic co-treatment,  mean 
number (±SD) 
1.15 (±1.01) 2.04 (±1.05) 1.4 (±1.13) 1.6 (±1.07) 
Any nephrotoxic co-treatment (%) 69 (69) 48 (96) 56 (74.7) 61 (81.3) 
- - Inc. aminoglycosides (%) 2 (2) 7 (14) 5 (6.7) 4 (5.3) 
- - Inc. diuretics (%) 31 (31) 35 (70) 34 (45.3) 32 (42.7) 
- - Inc. antifungal agent (%) 1 (1) 8 (16) 5 (6.7) 4 (5.3) 
- - Inc. NSAIDs (%) 53 (53) 25 (50) 30 (40) 48 (64) 
- - Inc. ACE inhibitor (%) 23 (23) 18 (36) 21 (28) 20 (26.7) 
- - Other (%) 5 (5) 8 (16) 6 (8) 8 (10.7) 
Vancomycin parameters     
Mean duration, days (±SD) 14.7 (±10.5) 19.5 (±14.15) 14.4 (±10.4) 18.15 (±13.2) 
Mean trough conc., mg/L (±SD) 15.5 (±5.3) 16.2 (±5.3) *12.0 (±3.3) *19.5 (±4.12) 
Mean peak conc., mg/L (±SD) 23.6 (±6.4) 27.3 (±15.7) 22.8 (±5.14) 27.02 (±13.8) 
Mean daily dose, g (±SD) 1.6 (±0.6) 1.3 (±0.6) 1.51 (±0.5) 1.5 (±0.7) 
Mean total dose, g (±SD) 22.7 (±18.7) 26.4 (±22.01) 22.3 (±18.8) 25.7 (±20.9) 
Mean Vancomycin clearance (±SD) 3.8 (±1.8) 3.06 (±1.6) 4.3 (±1.9) 2.9 (±1.3) 
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Volume of distribution (±SD) 126.3 (±41.4) 155.7 (±79.4) 151.1 (±63.9) 121.1 (±48.3) 
Creatinine parameters     
Mean sCr, µmol/L (±SD) *94.7 (±105.5) *119.6 (±60.5) 89.5 (±40.6) 116.5 (±124.8) 
Max sCr, µmol/L (±SD) *106.5 (±114.2) *214.4 (±140) 118.04 (±70.15) 166.9 (±171.8) 
Mean maximal sCr variation from 
baseline in % 
*9.2 *140.7 45.3 60.8 
Estimation of renal function     
eClCr with Cockcroft-Gault 
formula, mL/min (±SD)  
*85.4 (±33.03) *82.4 (±50.9) 93.4 (±45.5) 75.2 (±30.7) 
eGFR with MDRD formula, 
mL/min/1.73m² (±SD) 
*90.18 (±31.6) *80.8 (±39.0) 90.6 (±35.8) 83.4 (±32.8) 
sCr: serum creatinine; eClCr: estimated renal clearance of creatinine; eGFR: estimated glomerular filtration rate.  
*constructed outcome. 
Table 1: Variables contrasted for non-nephrotoxic vs nephrotoxic groups, and for non-overexposed vs 
overexposed groups. 
 
2.1. Risk factors for vancomycin-associated nephrotoxicity. 
 
Contrasting nephrotoxic group vs non-nephrotoxic group, the mean age was 67.8 (±13.9) vs 66.6 (±15.4) 
years. 70 vs 60% were male, with a mean body weight of 81.02 (± 17.1) vs 74.9 (± 17.2) kg. The most 
frequent comorbid condition was arterial hypertension in both groups (42 vs 49%). The majority of 
patients were treated for bloodstream infection (30%) vs. skin and soft tissues infection (42%). MRSA 
was in both cases the most frequent pathogens involved. Regarding clinical conditions, septic shock 
occurred almost three times more often in nephrotoxic group (8 vs 3%). 96 vs 69% of patients received 
a nephrotoxic co-treatment, with aminoglycosides and antifungal agents far more frequent in 
nephrotoxic group (14 vs 2% and 16 vs 1% respectively). Patients in nephrotoxic group were treated 
for a longer period (19.5 vs 14.7 days), but received smaller daily doses (1.3 vs 1.6 g). Nevertheless, the 
cumulative dose received over therapy was higher in the nephrotoxic group (26.4 vs 22.7 g). Creatinine 
parameters and estimation of renal function results differed, but this association is clearly constructed, 
as resulting from groups definition. 
 
Variables Univariate OR 
(95% CI) 
P value Multivariate OR 
(95% CI) 
P value 
Population characteristics     
Body weight 1.02 (0.99-1.04) 0.06   
Comorbid conditions     
Pre-existent renal failure 2.3 (1.0-5.4) 0.05   
Heart failure  3.12 (1.3-7.6) 0.012   
Pathogens     
MRSA 2.3 (1.05-5.0) 0.04   
Site of infection     
Bloodstream  1.8 (0.8-4.3) 0.2   
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Skin and soft tissues  0.41 (0.2-0.9) 0.03   
Intra-abdominal  14.4 (1.3-164) 0.03 30.2 (1.15-793) 0.04 
Clinical conditions     
Septic shock  3.7 (0.6-22) 0.16   
Concomitant exposure(CE) to      
any nephrotoxic treatment* 12.6 (2.8-57) 0.001   
aminoglycosides 8.13 (1.2-53) 0.03 10.9 (1.9-60) 0.006 
diuretics 5.5 (2.4-12) <0.001 6.3 (2.8-14) <0.001 
antifungal agent 11.2 (1.3-93) 0.03   
ACE inhibitors 2.0 (0.9-4.5) 0.1   
Number of CE 2.4 (1.7-3.4) <0.001   
Therapy course     
Vancomycin overexposure 4.12 (2.09-8.15) <0.001 4.8 (2.14-10.7) <0.001 
Duration of therapy 1.03 (1.0-1.07) 0.05   
Mean dose per day 0.99 (0.99-1.00) 0.08   
Mean trough concentration 1.09 (1.016-1.18) 0.015   
Pharmacokinetics parameters     
Mean Vancomycin clearance 0.7 (0.6-0.9) 0.002   
Vancomycin volume of distribution 1.01 (1.00-1.02) 0.008   
*from treatments retrieved for the study.  
Only variables with p value inferior to 0.2 are shown here 
Table 2: Results of univariate and multivariate analysis for vancomycin-associated nephrotoxicity. 
 
After univariate analysis, heart failure, MRSA, skin and soft tissues infection, intra-abdominal infection, 
septic shock and concomitant exposure to aminoglycosides, diuretics or antifungal agents are found to 
be significantly associated with vancomycin-induced nephrotoxicity. Odds ratio, 95% confidence 
interval and p values for these factors are shown in table 2. Vancomycin overexposure is of course again 
associated with nephrotoxicity (OR 4.12, [95%CI] 2.09-8.15, p<0.001). Duration of therapy is barely 
significant (OR 1.03, [95%CI] 1-1.07, p = 0.05). Interestingly, variables such as age, sex, obesity, 
vancomycin daily and total doses were not found to be risk factors. Detailed univariate analysis with 
Odds ratio, 95% CI and p values are shown in appendix 3.  
 
In the multivariate analysis, vancomycin-induced nephrotoxicity remained associated with vancomycin 
overexposure (OR 4.8, p<0.001), aminoglycosides (OR 10.9, p=0.006), diuretics (OR 6.3, p<0.001) and 
intra-abdominal infections (OR 30.2, p=0.04). Conversely, inclusion of vancomycin overexposure as a 
risk factor made MRSA and antifungal agents to be dropped out from the list of predictors in the 
multivariate analysis. 
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2.2. Risk factors for vancomycin overexposure. 
 
Contrasting overexposed group vs non-overexposed group, the mean age was 69.8 (±13.9) vs 64.2 
(±15.4) years. 65.3 vs 61.3% were male, with a mean body weight of 75.11 (± 17.3) vs 78.8 (±17.2) kg. 
While the most frequent comorbid condition was arterial hypertension in both groups, it is interesting 
to note the marked difference for pre-existent renal failure (30.7 vs 18.7%) and heart failure (34.7 vs 
12%). The majority of patients were treated for skin and soft tissues infection in both groups, with 
bloodstream infection being more frequent in the overexposed group (26.7 vs 17.3%). MRSA was in both 
cases the most frequent pathogens involved (44 vs 25.3%). 81.3 vs 71.7% of patients received a 
nephrotoxic co-treatment, with NSAIDs being quite more frequent in overexposed group (64 vs 40%). 
Patients in overexposed group were treated for a longer period (18.15 vs 14.4 days), daily dose being 
similar (1.5 g/L in both groups) but cumulative dose received over therapy being higher (25.7 vs 22.3 
g/L). Mean creatinine levels were globally higher in overexposed group (116.5 vs 89.5 µmol/L), 
alongside an apparent impaired renal function estimation using either Cockcroft-Gault or MDRD 
formula.  
 
Variables Univariate OR 
(95% CI) 
P value Multivariate OR 
(95% CI) 
P value 
Population characteristics     
Age 1.02 (1.004-1.05) 0.03   
Comorbid conditions     
Arterial hypertension 1.6 (0.8-3.2) 0.16   
Pre-existent renal failure 2.3 (1.05-5.2) 0.04 2.5 (1.12-5.5) 0.03 
Heart failure  5.3 (2.12-13) <0.001 8.13 (2.6-25.2) <0.001 
Pathogens     
MRSA 2.8 (1.3-5.7) 0.007   
Streptococcus species 0.3 (0.05-1.6) 0.15   
Site of infection     
Bloodstream  2.0 (0.9-4.5) 0.11   
Meningitis 0.2 (0.02-2.01) 0.18   
Concomitant exposure(CE) to      
Number of CE 1.5 (1.08-2) 0.014 0.5 (0.3-0.9) 0.02 
any nephrotoxic treatment* 2.3 (1.04-5.1) 0.04   
diuretics 1.4 (0.7-2.8) 0.3   
NSAIDs 2.5 (1.3-5.1) 0.008 5.4 (2.2-13.5) <0.001 
Therapy course     
Mean duration 1.03 (1.004-1.07) 0.03   
Mean peak concentration 1.06 (1.0-1.14) 0.08   
Renal function     
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Vancomycin-associated nephrotoxicity 4.12 (2.09-8.15) <0.001 5.2 (2.3-11.9) <0.001 
Mean Creatinine level 1.01 (1.002-1.02) 0.011   
Max Creatinine level 1.008 (1.004-1.01) <0.001   
eClCr with Cockcroft-Gault formula, 
mL/min  
0.98 (0.97-0.99) 0.004   
eGFR with MDRD formula, 
mL/min/1.73m²  
0.99 (0.98-1.002) 0.11   
*from treatments retrieved for the study.  
Only variables with p value inferior to 0.2 are shown here  
Table 3: Results of univariate and multivariate analysis for vancomycin overexposure. 
 
After univariate analysis, heart failure, MRSA, skin and soft tissues infection, intra-abdominal infection, 
septic shock and concomitant exposure to aminoglycosides, diuretics or antifungal agents are found to 
be significantly associated with vancomycin-induced nephrotoxicity. Odds ratio, 95% confidence 
interval and p values for these factors are shown in table 3. Induced nephrotoxicity was evidently again 
associated with overexposure (OR 4.12, [95%CI] 2.09-8.15, p<0.001). Duration of therapy is barely 
significant (OR 1.03, [95%CI] 1-1.07, p = 0.05). Again, variables such as body weight, sex, obesity, 
vancomycin daily and total doses were not found to be risk factors. Detailed univariate analysis with 
odds ratio, 95% CI and p values are shown in appendix 4.  
 
In the multivariate analysis, vancomycin overexposure was associated with vancomycin-associated 
nephrotoxicity (OR 5.2, p<0.001) along with NSAIDs (OR 5.4, p<0.001), pre-existent renal failure (OR 
2.5, p=0.03) and heart failure (OR 8.13, p<0.001). Surprisingly, an odds ratio <1 was found for the 
number of concomitant exposures to other nephrotoxic treatments (OR 0.5, p=0.02). Inclusion of 
nephrotoxicity as a risk factor for overexposure led to drop out MRSA from the multivariate analysis. It 
is here interesting to note that renal function variables, especially the estimated creatinine clearance 
with Cockcroft-Gault equation, mean and maximal creatinine levels, outshined vancomycin-associated 
nephrotoxicity association with overexposure (OR 2.41, p>0.2) when included in the multivariate 
model! But considering that these variables are directly influenced by vancomycin overexposure, 
although they contribute to its occurrence (vicious circle effect), they were left out the final multivariate 
model.  
 
3. Temporal link between vancomycin and creatinine changes. 
3.1. Cross correlations approach  
 
As explained earlier, only vancomycin trough-concentrations with a creatinine sampled the same day 
were kept for this exploration. First, a simple rank-based correlation found vancomycin and creatinine 
to be positively correlated (Spearman’s rho R = 0.3, p value <0.001). This is another indication of 
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association between induced-nephrotoxicity and overexposure (creatinine levels tend to rise when 
trough-concentration are high). Variables were then created by shifting creatinine values up to 3 lags in 
the past (sCr -1, sCr -2 and sCr -3) and in the future (sCr +1, sCr +2, sCr +3). Correlation between a 
trough-concentration and creatinine values from the past and the future were then assessed using 
Spearman’s rank correlation coefficient (R). 
 
Variables  VTr sCr sCr -1 sCr -2 sCr -3 sCr +1 sCr +2 sCr +3 
VTr R 1        
 p         
sCr R 0.3 1       
 p <0.001        
sCr -1 R 0.06 0.9 1      
 p 0.4 <0.001       
sCr -2 R 0.14 0.7 0.8 1     
 p 0.2 <0.001 <0.001      
SCr -3 R 0.15 0.6 0.6 0.8 1    
 p 0.3 <0.001 <0.001 <0.001     
sCr +1 R 0.4 0.9 0.7 0.6 0.3 1   
 p <0.001 <0.001 <0.001 <0.001 0.1    
sCr +2 R 0.4 0.7 0.6 0.3 0.3 0.9 1  
 p <0.001 <0.001 <0.001 0.1 0.1 <0.001   
sCr +3 R 0.4 0.6 0.3 0.3 0.5 0.7 0.9 1 
 p <0.001 <0.001 0.1 0.1 0.1 <0.001 <0.001  
sCr: serum creatinine; VTr: vancomycin trough-concentration. 
Significant correlations are shown in bold. 
Table 4: Cross correlations matrix between present vancomycin trough-concentration and creatinine 
levels through time (from 3 shifts in the past to 3 shifts in the future). 
 
Cross correlations results are presented in table 4. Vancomycin trough-concentration is significantly 
correlated with creatinine levels of the future (R = 0.4, p<0.001 for 1, 2 and 3 shifts), but less with levels 
from the past. Creatinine is strongly auto-correlated with both levels from the past and the future (with 
R values decreasing when shift increases). The same approach was applied to test cross-correlations 
between creatinine and past/future trough-concentrations, with results shown in appendix 5. 
Creatinine level is positively correlated with trough-concentrations in the past (R = 0.4, p<0.001 for 1 
and 2 shifts; R = 0.4, p = 0.003 for 3 shifts). Vancomycin seems to be less auto-correlated as creatinine 
(p<0.001 only for 1 shift in the past and in the future). 
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Cross correlations were also performed between vancomycin current dosage and past/future trough-
concentrations (table 5). Interestingly, dosage is not correlated with simultaneous trough-
concentration but positively correlated with the future ones (R = 0.3, 0.3 and 0.3 with p <0.001, 0.02 and 
0.011 for 1, 2 and 3 shifts respectively) and negatively with the past ones (R = -0.4, -0.4 and -0.3 with p 
<0.001, <0.001 and 0.05 for 1, 2 and 3 shifts respectively). 
 
Variables  Dose VTr VTr -1 VTr -2 VTr -3 VTr +1 VTr +2 VTr +3 
Dose R 1        
 p         
VTr R 0.1 1       
 p 0.09        
VTr -1 R - 0.4 0.3 1      
 p <0.001 <0.001       
VTr -2 R - 0.4 - 0.03 0.4 1     
 p <0.001 0.8 <0.001      
VTr -3 R - 0.3 0.04 0.02 0.4 1    
 p 0.05 0.8 0.9 0.014     
VTr +1 R 0.3 0.3 - 0.03 0.04 - 0.09 1   
 p <0.001 <0.001 0.8 0.8 0.7    
VTr +2 R 0.3 - 0.03 0.04 - 0.09 0.2 0.3 1  
 p 0.02 0.8 0.8 0.7 0.3 0.003   
VTr +3 R 0.3 0.04 - 0.09 0.2 0.09 0.2 0.5 1 
 p 0.011 0.8 0.7 0.3 0.8 0.09 <0.001  
VTr: vancomycin trough-concentration. 
Significant correlations are shown in bold 
Table 5: Cross correlations matrix between present vancomycin dose and trough concentrations 
through time (from 3 shifts in the past to 3 shifts in the future). 
 
Finally, cross correlations between current dose and past/future creatinine levels finds dose negatively 
correlated with every shifts of creatinine either in the past or in the future (p <0.05 for all shifts). 
Detailed results are shown in appendix 6. 
 
3.2. Granger causality test approach. 
 
Granger causality test was used to evaluate how vancomycin and creatinine act on one another. 
Prediction of future trough-concentrations based on past ones somewhat improved when 1 shift of 
past creatinine level was included in the model already including past vancomycin levels, though it 
was not significant. (Likelihood ratio for model improvement: LR 3.06, p = 0.08). When 3 shifts of past 
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creatinine levels were included, prediction failed to be better (LR 0.29, p = 0.96). Reciprocally, 
prediction of future creatinine levels based on past ones was enhanced when 1 shift of vancomycin 
trough concentration was included in the model based on past creatinine values, though it was again 
not significant (LR 3.12, p = 0.08). When 3 shifts were included, prediction failed to better (LR 0.35, p = 
0.95).  
 
4. Illustrative cases.  
Fig. 2-5: Clinical courses showing vancomycin levels with daily doses (g/d), and creatinine (sCr) levels 
over days. 
 
 
Fig.2: V0C0 male patient, 38 years old, 69kg, treated for a S. epidermidis bloodstream infection. 
Target trough was maintained all along therapy. 
 
 
 
Fig.3: V0C1 male patient, 50 years old, 86kg, known for a heart failure, treated for a MRSA 
bloodstream infection and taking diuretics, NSAIDs and ACE inhibitors as co-treatment. A 
maximal 129% rise from baseline in creatinine levels occurred shortly after dosage 
intensification of vancomycin. 
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Fig.4: V1C0 female patient, 78 years old, 69kg, known for a heart failure with a S. epidermidis 
acute prosthetic joint infection. During five days, she received both aminoglycosides and 
vancomycin. She presented one trough-concentration 23.9 mg/L, leading to immediate dosage 
adaptation. 
 
 
 
Fig.5: V1C1 male patient, 60 years old, 110 kg, known for obesity, arterial hypertension, 
diabetes and heart failure, who received vancomycin for a severe MRSA osteomyelitis requiring 
high doses of vancomycin to ensure therapeutic effect. After a first disruption due to 
overexposure, vancomycin was started again and kept on despite 3 new consecutive trough-
concentrations >20mg/L. Nephrotoxicity occurred some days later, persisting despite 
vancomycin disruption. The patient was then found to suffer from acute tubular necrosis. 
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Discussion 
 
This retrospective observational study recorded extensive medical data for 150 patients, randomly 
sampled among a population of 836 patients matching our inclusion criteria, who received a 
vancomycin therapy with therapeutic drug monitoring (TDM) surveillance. Chronological courses of 
vancomycin therapy were rebuilt for each patient of the reviewed sample in order to describe precisely 
the variations in vancomycin and creatinine levels along time.  
 
A clear association was confirmed between vancomycin overexposure and occurrence of vancomycin-
induced nephrotoxicity (OR 4.12, p <0.001). This association was robust and persisted without 
important changes when other risk factors were included in multivariate predictive models. The 
frequency of nephrotoxicity occurrence in patients meeting overexposure criteria (45% versus 16.5% 
without overexposure) is compatible with other observations in the literature. Among our study 
patients, nephrotoxic episodes were quickly reversible without persistent renal damages in most cases, 
except in three cases where patients developed acute tubular necrosis.  
 
Regarding vancomycin-associated nephrotoxicity, it is interesting to note that none of age, sex, body 
weight or obesity were found to be risk factors. Univariate analysis shows however body weight to be 
associated with a 20% risk increase for every 10 kg. If duration of therapy and total dose received are 
longer and higher in the nephrotoxic group, the mean daily dose of vancomycin is lower, probably 
reflecting dosage adaptation for patients with kidney function impairment. According to our logistic 
regression analysis, renal aggravating factors such as concomitant treatment with aminoglycosides and 
diuretics were found to significantly add to the risk of vancomycin-associated nephrotoxicity. 
Abdominal infections are strongly associated with nephrotoxicity, but this result is based on little 
number of patients. Due to associations with vancomycin overexposure, some factors identified by 
univariate analysis, such as MRSA infection, were left out of the multivariate model. This makes sense 
as the treatment of MRSA infection requires higher trough-concentrations, thus being at higher risk of 
overexposure.  
 
Pre-existing renal impairment or factors decreasing renal perfusion, such as heart failure and NSAIDs 
co-treatment, increase significantly the risk of vancomycin overexposure. This may be suggestive of 
insufficient vancomycin dosage adaptation in these cases. Through the univariate analysis, age is 
associated with a 20% risk increase for every ten years period. Vancomycin overexposure is more 
frequent in the presence of renal impairment. This reflects as well in vancomycin clearance, which is 
diminished in the overexposed group of patients (2.9 mL/min vs 4.3 mL/min). Mean daily dose and total 
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cumulative dose were not found to be risk factors for overexposure, suggesting that dosage adaptation 
is eventually made when trough-concentrations are rising. Another point of interest is renal function 
variables, especially the estimated creatinine clearance with Cockcroft-Gault equation, mean and 
maximal creatinine levels, outshining associated nephrotoxicity association with overexposure when 
included in the multivariate model. This can be related to the vicious circle described in the introduction. 
 
With this vicious circle effect, it is difficult to determine the ultimate origin of the reciprocal causal 
relationship between induced-nephrotoxicity and overexposure. While cross-correlations tend to show 
some antecedence of vancomycin on creatinine changes, formal Granger tests suggest non-significant 
trends for reciprocal causation between vancomycin overexposure and occurrence of nephrotoxicity 
(p=0.08 both ways). This suggests that vancomycin overexposure might have some precedence in 
triggering renal impairment, instead of the opposite. As daily doses of vancomycin are positively 
correlated with future trough-concentrations but negatively with the past ones, this probably reflects 
here again a dosage adaption by prescribers in response to high trough-concentrations. The doses of 
vancomycin are themselves negatively correlated with creatinine levels both in the past and in the 
future, reflecting the dosage adaptation based on the renal function. Altogether, our exploration of 
chronological relationships between the development of vancomycin overexposure and of 
nephrotoxicity is consistent with the view that dosage adjustments for renal impairment are actually 
done by the prescribers, but possibly often with some delay, thus allowing vancomycin accumulation up 
to levels associated with nephrotoxicity.  The vicious cycle can then progress, still encouraged by some 
delays in the readjustment of vancomycin dosages.   
 
This study has several limitations. First, the number of patients included was limited, with a possible 
failure to statistically identify some significant trends despite real significance. The number of patients 
composing our reviewed population was determined by extrapolation, a margin of error is still existing 
regarding the model coefficients and the odds ratios that we obtained. Our study could have suffered 
from a selection bias, as we recruited only patients with TDM surveillance during vancomycin therapy, 
meaning they could have been suspected to be more likely subjects to nephrotoxicity by the medical 
team in charge. However, the utilization of TDM to monitor vancomycin treatment is widespread in our 
hospital, and it is very unlikely that a significant number of patients receiving vancomycin could escape 
the study because they had no TDM. The exclusion of patients matching the C1’ criterion but failing to 
match the ultimate C1 criteria may be questionable regarding the representativeness of the sample. 
The follow-up of vancomycin trough-concentrations and creatinine in medical records was quite 
variable from a patient to another and information regarding population characteristics was sometimes 
unclear. We consider that the exclusion of these patients of uncertain status was the best approach, 
although it can have unduly cleaned up our results to some extent. Finally, our results possibly deserve 
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further modelling using modern population pharmacokinetic/pharmacodynamic approaches. This 
analysis was out of the scope of this study, but could lead to the elaboration of prediction tools possibly 
able to foresee the “trajectory” of vancomycin exposure and renal function in a given patient, so that 
corrective actions on dosage can be decided earlier and treatment safety is improved.  
 
In conclusion, this study confirms a clear and marked association between vancomycin-associated 
nephrotoxicity and vancomycin overexposure. Medications or comorbid conditions favouring renal 
impairment, either by direct nephrotoxicity or by causing pre-renal dysfunction, are important risk 
factors to be taken into account by prescribers. This emphasizes the importance of thorough dosage 
adaptation during vancomycin therapy, with the aid of TDM and creatinine follow-up. 
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